Title:
ＦＡＳＮを阻害するための新規化合物および組成物
Document Type and Number:
Japanese Patent JP6790040
Kind Code:
B2
Abstract:
The present invention relates to a list of specific 2-hydroxy-1-{4-[(4-phenylphenyl)carbonyl]piperazin-1-yl}ethan-1-one derivatives and related compounds as fatty acid synthase (FAS or FASN) inhibitors for treating cancer and pharmacutical compositions thereof .An illustrative compound of the invention is shown below:
More Like This:
Inventors:
Kennes, W. Bear
David Earl. Lancia Jr.
Hong Bin Lee
James Loch
Way Lou
Matthew, W. Martin
David, S. Millan
Shawn, E. Earl Stiller
Mark, Jay. Thebbe
David Earl. Lancia Jr.
Hong Bin Lee
James Loch
Way Lou
Matthew, W. Martin
David, S. Millan
Shawn, E. Earl Stiller
Mark, Jay. Thebbe
Application Number:
JP2018203058A
Publication Date:
November 25, 2020
Filing Date:
October 29, 2018
Export Citation:
Assignee:
FORMA THERAPEUTICS,INC.
International Classes:
C07D207/27; A61K31/337; A61K31/4188; A61K31/4745; A61K31/495; A61K31/496; A61K31/497; A61K31/506; A61K31/513; A61K31/517; A61K31/519; A61K31/55; A61K31/675; A61K31/704; A61K31/7048; A61K31/7068; A61K33/24; A61K45/00; A61P1/04; A61P1/18; A61P3/00; A61P3/04; A61P7/00; A61P9/10; A61P11/00; A61P11/06; A61P13/02; A61P13/08; A61P13/10; A61P13/12; A61P15/00; A61P17/00; A61P17/06; A61P19/02; A61P19/08; A61P19/10; A61P25/00; A61P29/00; A61P31/12; A61P31/14; A61P31/18; A61P31/20; A61P31/22; A61P35/00; A61P35/02; A61P37/02; A61P37/06; A61P37/08; A61P43/00; C07D209/08; C07D209/18; C07D209/24; C07D209/34; C07D209/42; C07D209/44; C07D211/34; C07D213/56; C07D213/61; C07D213/65; C07D213/69; C07D213/75; C07D213/81; C07D213/82; C07D215/06; C07D215/12; C07D215/18; C07D215/20; C07D215/227; C07D217/04; C07D217/18; C07D223/16; C07D231/12; C07D231/56; C07D233/34; C07D233/76; C07D235/06; C07D235/08; C07D235/12; C07D235/16; C07D235/26; C07D239/28; C07D239/74; C07D241/04; C07D241/38; C07D249/06; C07D249/08; C07D257/04; C07D261/20; C07D263/56; C07D263/57; C07D263/58; C07D271/06; C07D271/12; C07D275/02; C07D277/40; C07D277/62; C07D277/66; C07D285/12; C07D285/14; C07D295/192; C07D305/06; C07D305/08; C07D307/85; C07D309/08; C07D401/04; C07D401/10; C07D403/04; C07D403/10; C07D405/04; C07D405/06; C07D405/12; C07D413/10; C07D413/12; C07D417/04; C07D417/12; C07D471/04; C07D487/04; C07D491/048; C07D495/04; C07D513/04
Domestic Patent References:
| JP2007502266A | ||||
| JP2003508509A | ||||
| JP2007537300A | ||||
| JP2011530513A | ||||
| JP2011511078A | ||||
| JP2007531752A | ||||
| JP2012528179A |
Foreign References:
| WO2013033068A1 | ||||
| WO2013028495A1 | ||||
| CN102627610A | ||||
| WO2005073186A1 | ||||
| WO2011140190A1 | ||||
| WO2012122391A1 | ||||
| WO2011140296A1 |
Other References:
AICHER, T. et al.,Journal of Medicinal Chemistry,2000年,43(2),p.236-49
Attorney, Agent or Firm:
Hidesaku Yamamoto
Natsuki Morishita
Takatoshi Iida
Daisuke Ishikawa
Kensaku Yamamoto
Natsuki Morishita
Takatoshi Iida
Daisuke Ishikawa
Kensaku Yamamoto